SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are under pressure amid staggered IPO lockup releases that make additional shares eligible for sale, with traders debating whether potential insider selling will add to the decline or is already priced in. Broader weakness in AI and semiconductor stocks and concerns about valuation and customer concentration weigh on sentiment, while some investors are buying the dip.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention amid a sharp futures rebound after a technology-led selloff, with traders debating whether it signals a sustained recovery or is only a short-covering bounce that could fade. Discussion also centers on Black Monday anniversary fears and upcoming Big Tech earnings, which could test sentiment around AI-related stocks.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial is the focus, with traders watching for the 80th death event that triggers final analysis; the last disclosed count was 78, and the company has not confirmed that the threshold has been reached. The prolonged wait and company silence fuel opposing views: some see a possible survival benefit from GPS, while others worry about the delay and question speculation that ASH embargoes or the companys booth signal an upcoming readout; shares have faced sharp selling.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp rebound in index futures after a tech-led selloff has fueled discussion around the 1987 Black Monday anniversary and upcoming Big Tech earnings. Traders are split on whether the move signals a recovery or is a low-volume short-covering bounce that could fade.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a broad selloff in AI infrastructure and neocloud stocks, as traders debate whether high financing costs, debt exposure and uncertain returns make the sectors data-center expansion unsustainable; concerns about CoreWeaves credit risks are also weighing on peers. Bulls argue Nebius has a stronger balance sheet, durable AI demand and valuable customer relationships, while bears see further downside and a valuation reset.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

ESMO data on Iovances lifileucel is driving attention, especially mature frontline melanoma results for the lifileucelpembrolizumab combination and preliminary sarcoma activity. Traders largely view the melanoma durability data as encouraging support for the ongoing Phase 3 trial, while debating whether the small sarcoma cohort and its lower response rate versus an earlier cut meaningfully strengthen the case for expansion.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassians push to a new 52-week high, attributed to enterprise demand and customers migrating to its cloud products, has drawn attention. Traders are split between viewing the move as a breakout and expecting resistance or a pullback after the sharp run.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas move to fresh highs is being linked to its stablecoin-powered payment service and Chinas approval for the company to prepare a domestic card-clearing business. Traders are broadly bullish on the breakout and new payment opportunities, while some caution that the rally looks extended and may pull back.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

RIOT is drawing attention amid a sharp selloff across Bitcoin miners and AI/data-center-linked stocks, with traders pointing to Bitcoin weakness, broader market pressure, and doubts about the sectors capital-intensive AI pivot. Many are frustrated that RIOT has fallen even when Bitcoin holds up, while others are buying the dip and debating whether further downside lies ahead.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is drawing attention after a sharp price and volume surge, with traders noting its strength even as the broader crypto market weakened and speculating that buying activity could signal something developing; no specific catalyst is confirmed. The reaction is divided between buyers anticipating a breakout and skeptics warning the move may fade like prior pumps, while some point to Flexas payment-and-collateral thesis and AMPs relationship with ANVL as longer-term context.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Emergent BioSolutions CFO transition is driving the latest discussion, with Richard Lindahl set to retire and treasurer Frank Vargo to serve as interim CFO starting in 2027. Traders are split between viewing it as a routine, planned succession and worrying that the timing and lack of a permanent replacement signal financial or accounting concerns ahead of the Q3 report; those concerns remain speculation.

Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026

Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, November 2, 2026, at 5:00 p.m. eastern time to discuss the financial results for the third quarter of 2026. Participants can access the conference call via webcast and also by visiting the Investors page of Emergents...

Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?

Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'

Equity

No plague case has been confirmed, and no government orders have been announced, but outbreak-linked stocks jumped anyway.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBSPR NewswireNEW YORK, Sept. 24, 2026 NEW YORK, Sept. 24, 2026...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBSPR NewswireNEW YORK, Sept. 17, 2026 NEW YORK, Sept. 17, 2026...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS PR Newswire NEW YORK, Sept. 10, 2026 NEW YORK, Sept. 10, 2026...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS PR Newswire NEW YORK, Aug. 27, 2026 NEW YORK, Aug. 27, 2026...

Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Emergent BioSolutions Inc. (Emergent BioSolutions or the Company) (NYSE: EBS) investors concerning the Companys possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN EMERGENT BIOSOLUTIONS...

Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Emergent BioSolutions Inc. (Emergent BioSolutions or the Company) (NYSE: EBS) on behalf of investors concerning the Companys possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON EMERGENT BIOSOLUTIONS...

EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Emergent BioSolutions Inc. (Emergent or the Company) (NYSE: EBS) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

Investors are debating if the CFO's planned retirement is a strategic move or a signal of deeper underlying accounting concerns.

Anticipation is building for the upcoming Q3 earnings call on November 2nd as traders look for clues on financial health.

Current Price	$6.38
Prev Close	$7.18
Open	$6.64
Dividend Yield	0.00%
50-Day Moving Average	$6.09
Beta	2.03
Avg. Volume	1.13M
PE Ratio	-1.80

52-Week High	$14.06
52-Week Low	$4.36
Market Capitalization	$327.12M
EPS (Annual)	$0.9277
Price to Book	0.96
Revenue Per Employee	$825,444.44

Feed

News

Sentiment

Earnings

Fundamentals

Info

EBS Fundamentals